Stage 4 PC Longevity: Anyone have prostate cancer more than 10 years?

Lutetium-177 PSMA therapy is based on the notion that Lu-177 can stick to the surface of the cell membranes that make PSMA. Lutathera and Pluvicto, two drugs with lutetium, were the first to get FDA approval. Radiologists can use it if the tumor has spread to other body parts and isn't responding to chemo or hormone therapy.
Radium-223 dichloride, Xofigo, is used to treat advanced prostate cancer metastasizing to the bones. Radium's structure is also similar to that of Calcium, which is the main element in bone tissue. This similarity makes it easier for Ra-223 to get into bone metastases and kill cancer cells. Since there are no cancerous cells in the internal organs, this radioligand is given.
Actinium-225 PSMA therapy is a novel radioligand-based approach to treating cancerous tumors. The medication molecule can bind to the protein in the same way that Lutetium can. It is used in place of Lutathera in cases where the latter medication is ineffective against prostate cancer.

share charts https://airomedical.com/blogs/treatment-guides/what-is-better-actinium-radium-or-lutetium-for-prostate-cancer
The results of many clinical trials show the efficiency of Lu-177 treatment:
Increasing the 5-year survival rate by 30%;
Decreasing the risk of recurrence;
Improving the quality of life in 70% of patients.
The investigations in Ac-225 efficacy presented:
Lowering levels of an indicator of prostate cancer PSA in 80% of patients;
Decreasing of 50-80% of metastases;
Increasing the life expectancy.
The studies in Ra-223 showed:
Increasing average survival;
Decreasing risks of death by 30%;
Reducing pain and making the life quality higher.
We can say that the Lutetium-177, Actinium-225, and Radium-223 therapy significantly improve prostate cancer patients' condition. It makes a longer life expectancy because it is successful and does not cause significant harm.

sharing https://airomedical.com/blogs/treatment-guides/what-is-better-actinium-radium-or-lutetium-for-prostate-cancer

https://airomedical.com/blogs/treatment-guides/what-is-better-actinium-radium-or-lutetium-for-prostate-cancer

My Xtandi not working after a year Jan Now they want chemo for spinal mets

Psa 9.8 up frpm 1.7 year ago Ideas welsome

Colleen
PSA almost undetectable, and testosterone at 7 (lowest reading).
Side effects of therapy:
Hot flushes
Not as strong 30 percent off)
Not really fatigued
Testicles feel softer
Dry skin
Labs really all normal excepting a small drop in rbc and hematocrit
Long term, who knows--worry about cardio and osteo

@jacksgland, your timeline offers hope to many, living with stage 4 is possible.

How are you doing on Relugolix and Xtandi?

My husband was first diagnosed in 2005. After brachytherapy and external beam radiation, the cancer was in remission until 2011. When it recurred, he referred himself to Mayo and has been a patient of Dr Kwon ever since. After various oral meds and spot radiation to the spinal mets, he had chemo with taxotere in 2016. More spot radiation since, along with Lupron and Zytiga. After three years on Zytiga, another recurrence. More spot radiation until the spinal mets became too numerous in the last few months. Both Dr Kwon and the local medical oncologist recommended Lutetium 177/Pluvicto, and the first infusion is on January 17. Because my husband has already had chemo and radiation and oral meds, he was deemed eligible after a PSMA PET showed many spots with receptors for L177 to hit. The plan is for six infusions six weeks apart, the current standard protocol, as long as they are effective. The projected outcome is not a cure, but an extended remission.

What is the projected out come? Did he have to do chemo first How many injections of 177 planned

Bless you

If spot radiation is not advisable, Pluvicto/Lutetium 177 may be appropriate. That is what my husband is about to start for spinal mets after Zytiga/abiraterone stopped working after 3 years.